Gilead Sciences (NASDAQ:GILD)

Medical vaccine in shoulder, vaccination

What Analysts Are Prescribing Gilead After Earnings

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday. The stock hit a new multiyear low on Wednesday and pushed even lower on Thursday to a price ...
Read Full Story »
Wow

Major Biotechs Scare Off Loads of Short Sellers

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »
Stock Price

Vista Outdoor, Fossil Group Dive into Thursday’s 52-Week Low Club

February 9, 2017: Here are four stocks trading with relatively heavy volume among 35 equities making new 52-week lows in Thursday's session. On the NYSE, advancers led decliners nearly 2 ...
Read Full Story »
Stock Price

Gilead Sciences, Fitbit Plunge into Wednesday’s 52-Week Low Club

February 8, 2017: Here are four stocks trading with relatively heavy volume among 69 equities making new 52-week lows in Wednesday's session. On the NYSE, advancers led decliners by less than ...
Read Full Story »
thumbs up and down

What Analysts Are Saying About Gilead Sciences After Earnings

After Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday, the stock hit a new multiyear low, not seen since 2014. Across the board analysts saw ...
Read Full Story »
Prescription Drugs, Pills

Wednesday’s Biggest Biopharma Movers

Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss. Although ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: Broadcom, Cheniere, Gilead, Microchip Tech, Twitter, Lennar, Bankrate and Many More

Stocks were indicated slightly lower on Wednesday, although a 20-point Dow drop and three-point S&P 500 retreat are hardly worth getting down in the dumps about. After all, the Dow ...
Read Full Story »
burning cash

Why Gilead Earnings Were Not Up to Snuff

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue, compared with the ...
Read Full Story »
Medical vaccine in shoulder, vaccination

What to Expect From Gilead Earnings

Gilead Sciences Inc. (NASDAQ: GILD) is set to report its fourth-quarter financial results after the markets close on Tuesday. The consensus estimates call for $2.61 in earnings per share (EPS) ...
Read Full Story »
ThinkstockPhotos-475180302

Top 7 Earnings for the Week Ahead

24/7 Wall St. has put together a preview of some of the major companies reporting their quarterly results this week as earnings season is winding down. The Trump rally has ...
Read Full Story »
buy sell stocks

7 Dirt Cheap S&P 500 Value Stocks for Massive Upside Potential for 2017 and 2018

It is probably an understatement that the magnitude of the post-election rally has shocked many investors. Now many investors have been repositioning their investments as the Dow Jones Industrial Average ...
Read Full Story »
biotech word cloud

Short Sellers Back Off Major Biotechs

The short interest data are out for the most recent settlement date, January 13. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with ...
Read Full Story »
Stock Price

Gilead Sciences, DryShips Stuck in Tuesday’s 52-Week Low Club

January 24, 2017: Here are four stocks trading with relatively heavy volume among 48 equities making new 52-week lows in Tuesday's session. On the NYSE, advancers led decliners by about ...
Read Full Story »
Stock Price

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

January 23, 2017: Here are four stocks trading with relatively heavy volume among 56 equities making new 52-week lows in Monday's session. On the NYSE, advancers led decliners by about 8 ...
Read Full Story »
research

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

While the run since the Trump election and now the inauguration has been solid, there are some storm clouds on the horizon. Volatility has drifted to historic lows, while price-to-earnings ...
Read Full Story »